Research Article

Microglia show differential transcriptomic response to A β peptide aggregates ex vivo and in vivo

Karen N McFarland^{1,2,3} , Carolina Ceballos^{2,3,4}, Awilda Rosario^{2,3,4}, Thomas Ladd^{2,3,4}, Brenda Moore^{2,3,4}, Griffin Golde² , Xue Wang⁵, Mariet Allen⁶, Nilüfer Ertekin-Taner^{6,7}, Cory C Funk⁸, Max Robinson⁸, Priyanka Baloni⁸, Noa Rappaport⁸, Paramita Chakrabarty^{2,3,4}, Todd E Golde^{2,3,4}

Aggregation and accumulation of amyloid- β (A β) is a defining feature of Alzheimer's disease pathology. To study microglial responses to A β , we applied exogenous A β peptide, in either oligomeric or fibrillar conformation, to primary mouse microglial cultures and evaluated system-level transcriptional changes and then compared these with transcriptomic changes in the brains of CRND8 APP mice. We find that primary microglial cultures have rapid and massive transcriptional change in response to A β . Transcriptomic responses to oligomeric or fibrillar A β in primary microglia, although partially overlapping, are distinct and are not recapitulated in vivo where A β progressively accumulates. Furthermore, although classic immune mediators show massive transcriptional changes in the primary microglial cultures, these changes are not observed in the mouse model. Together, these data extend previous studies which demonstrate that microglia responses ex vivo are poor proxies for in vivo responses. Finally, these data demonstrate the potential utility of using microglia as biosensors of different aggregate conformation, as the transcriptional responses to oligomeric and fibrillar A β can be distinguished.

DOI [10.26508/lsa.202101108](https://doi.org/10.26508/lsa.202101108) | Received 26 April 2021 | Revised 27 May 2021 | Accepted 28 May 2021 | Published online 14 June 2021

Introduction

Alzheimer's disease (AD) is characterized by two hallmark pathologies, senile plaques containing amyloid- β (A β) aggregates and neurofibrillary tangles (NFTs) composed of hyperphosphorylated and aggregated τ . Amyloid plaques are the earliest manifestations of the disease process and can appear up to 20 yr before the onset of cognitive symptoms (Bateman et al, 2012). Amyloid pathology, in the absence of τ or neurodegenerative pathology, defines pre-clinical AD and is the first step along the Alzheimer's continuum in

humans (Vickers et al, 2016; Jack et al, 2018; Cummings, 2019). In longitudinal studies, amyloid deposition precedes τ accumulation which is more closely tied to cognitive decline relative to amyloid (Villemagne et al, 2013; Hanseeuw et al, 2019). Furthermore, genetic data strongly support a causal, triggering role for aggregation and accumulation of A β in AD (Kunkle et al, 2019)—including the well-studied APOE4 risk allele in late-onset AD, which reduces the clearance of A β from the brain (Liu et al, 2013). Yet, despite intensive study, the precise mechanism by which accumulation of A β aggregates trigger the degenerative phase of the disease is not well understood.

As the primary immune and phagocytic cell in the brain, the role of microglia has been of growing interest in AD and other neurodegenerative disorders. “Resting” microglia, which constitute up to 10% of the brain, constantly sample the surrounding brain microenvironment and can rapidly respond to an insult (Aguzzi et al, 2013). In AD, the presence of increased “reactive” microglial cells both around senile plaques and in areas of neurodegeneration is a well-established pathological feature (Dickson et al, 1988; Perlmutter et al, 1992; Dickson, 1997). Notably, A β ₄₂ fibrils and oligomers cause microglia activation resulting in the release of proinflammatory cytokines which may contribute to neurotoxicity (Jimenez et al, 2008; He et al, 2012; Dewapriya et al, 2013; Wang et al, 2016). Alterations in microglial activation states can also impact both amyloid and τ pathology in varying ways that are dependent on both the stimulus, the model system, and the pathology that is being assessed.

Over the last decade, a series of genetic studies has firmly linked microglial function to AD. Genetic studies of familial and late-onset AD implicate a large number of loci that contain immune genes in mediating the risk for AD (Harold et al, 2009; Lambert et al, 2009, 2013; Guerreiro et al, 2013; Jonsson et al, 2013; Jin et al, 2015; Carrasquillo et al, 2017; Sims et al, 2017; Kunkle et al, 2019). Furthermore, genetic studies identifying coding variants in three microglial-specific genes (PLCG2, ABI3, and TREM2) highlight the important role that microglia play during neurodegeneration (Guerreiro et al, 2013; Jonsson et al, 2013; Jin et al, 2014; Bellenguez

¹Department of Neurology, University of Florida, Gainesville, FL, USA ²Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA ³McKnight Brain Institute, University of Florida, Gainesville, FL, USA ⁴Department of Neuroscience, University of Florida, Gainesville, FL, USA ⁵Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA ⁶Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA ⁷Department of Neurology, Mayo Clinic, Jacksonville, FL, USA ⁸Institute for Systems Biology, Seattle, WA, USA

Correspondences: knmcfarland@ufl.edu; tgolde@ufl.edu

et al, 2017; Sims et al, 2017; Conway et al, 2018; van der Lee et al, 2019; Strickland et al, 2020). In addition, system-level data analysis of spatial, single-cell, single-nuclei, and bulk RNA-sequencing (RNA-seq) studies reveal perturbations in immune transcriptional networks as well as distinct subpopulations of microglia that are perturbed in the AD brain (Keren-Shaul et al, 2017; Krasemann et al, 2017; Conway et al, 2018; Friedman et al, 2018; Hammond et al, 2019; Li et al, 2019; Chen et al, 2020; Olah et al, 2020).

The study of microglial cells is challenging in that they are highly responsive to external stimuli and rapidly alter their phenotype once removed from the brain (Bennett et al, 2016). Indeed, system-level transcriptomic studies show that primary microglial cells are poor proxies for in vivo microglia (Butovsky et al, 2014). Even rapid isolation of microglial and subsequent “omic” analyses can be challenging as it is clear the isolation process is sufficient to induce some transcriptional—and likely functional changes. Nevertheless, many labs—including our own—study primary microglial cells in culture. In particular, the application of exogenous A β aggregates to microglia is a widely used methodology to study both how microglial respond to A β and how effectively the microglia can phagocytose and degrade A β .

Here, we used RNA-seq to examine the systems level response of primary microglia in culture to synthetic A β_{42} aggregates in either oligomeric (oA β) or fibrillar (fA β) form. Our analyses of the transcriptomic data show that microglial cells in culture show massive transcriptional changes when challenged with A β_{42} aggregates. Although some of the differentially expressed genes (DEGs) in response to the different forms of A β_{42} are altered similarly, many show differential expression in response to oA β or fA β . We also compared this global transcriptional response with A β_{42} in primary microglial cells in culture to transcriptomic data from a mouse model of amyloid deposition—the amyloid precursor protein (APP) transgenic CRND8 mouse—at 3–20 mo of age (Chishti et al, 2001). Subsequent comparisons of these datasets indicate that most A β transcriptional responses in microglia are largely not replicated in the intact brain. This comparison demonstrates that the transcriptional response to A β in primary cultures poorly reflect the response to A β by microglial cells in the mouse brain. These data amplify the message of several other recent studies indicating that one must be very cautious when using primary microglial cells cultured in isolation to infer mechanistic insights about microglial function in vivo.

Results

Large transcriptomic changes in primary microglia after A β treatment

Preformed oligomeric (oA β) or fibrillar (fA β) forms of A β_{42} peptide were applied to primary microglia cultures for 1- or 12-h. oA β and fA β were characterized by Western blot and a representative image is shown (Fig S1) demonstrating differences in the high molecular weight species between oligomeric and fibrillar A β preparations. After treatment, RNA was isolated and sequenced to identify transcriptional changes in primary microglia that are responsive to different conformations of A β_{42} peptide. As noted in the methods, these data along with the mouse CRND8 RNAseq data are publicly available and can be viewed using an interactive data portal. Using cutoff values of a *P*-value (adjusted for multiple comparisons) ≤ 0.05 and an absolute log₂ fold change of 0.5, we

identified acute transcriptional changes after fA β application after just 1-h (versus control) with 997 up-regulated and 960 down-regulated genes (Fig 1A and Table S1). Gene ontology (GO-MF) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified down-regulated genes as being enriched in cytoskeletal and extracellular matrix organization (i.e., tubulin binding, motor activity, and extracellular matrix structural constituent; Fig 1E and Tables S2 and S4), whereas up-regulated genes were involved in immune system responses (i.e., receptor for advanced glycation endproducts [RAGE] receptor binding and chemokine activity), and kinase activity (i.e., mitogen activated protein [MAP] kinase phosphatase activity; Fig 1F and Tables S3 and S5).

After 12-h of fA β treatment, we identified 1,755 up-regulated and 1,975 down-regulated genes when compared with control (Fig 1B and Table S6). Gene ontology (GO) and KEGG pathway analysis revealed enrichment of down-regulated genes involved in cytoskeletal and extracellular matrix organization (i.e., tubulin binding, motor activity, and extracellular matrix structural constituent) in addition to heparin binding and glycosaminoglycan binding (Fig 1E and Tables S8 and S10). Genes up-regulated after 12 h fA β treatment were enriched in genes involved with antigen processing (transporter associated with antigen [TAP] binding) and proteolytic activity (i.e., endopeptidase activator activity and threonine-type peptidase activity; Fig 1F and Tables S7 and S9).

We next examined the effect of a 12-h oA β treatment (versus control) on primary microglial cultures. We identified 1,608 up-regulated and 1,394 down-regulated genes after 12 h of oA β (Fig 1C and Table S11). GO and KEGG pathway analysis revealed that down-regulated genes are primarily involved in DNA transcription (i.e., DNA-binding transcriptional repressor activity and transcription cofactor binding; Fig 1C and E and Tables S13 and S15). Genes up-regulated by oA β treatment are enriched with GO terms suggestive of cell cycle involvement (i.e., anaphase-promoting complex binding and kinetochore binding; Fig 1F and Tables S12 and S14). A number of the top GO category hits overlap somewhat between the 1- and 12-h fA β treatments; however, many of the changes seen after oA β treatment stand in stark contrast to those seen after both fA β treatments.

To further examine differences and similarities in transcriptional changes between fA β and oA β treatments, we directly compared gene expression at 12 h of fA β treatment (numerator) against gene expression at 12 h of oA β treatment (denominator) to identify DEGs in these conditions. This comparison revealed disparate changes in transcriptional responses between the conformations of A β peptide and identified 982 up-regulated genes and 1,348 down-regulated genes in fA β versus oA β treatments (Fig 1D and Table S16). Affected down-regulated genes (down in fA β , up in oA β) primarily affected cell cycle and DNA-binding activities (i.e., DNA replication origin binding, kinetochore binding; Fig 1E and Tables S18 and S20), whereas up-regulated genes (up in fA β relative to oA β) were enriched in immune system responses (i.e., TAP binding, T-cell receptor binding; Fig 1F and Tables S17 and S19).

Primary microglia have unique transcriptional responses to A β conformations

To directly identify disparate changes in transcription in response to A β conformation, we compared the log-fold changes for DEGs in these A β treatments (Fig S2). We find a strong correlation ($R = 0.74$) when comparing treatments of fA β , 12-h (versus control) against

Figure 1. Differential gene expression in primary microglia after treatment with Aβ₄₂ oligomers (oAβ) or fibrils (fAβ). (A) Total changes in down- (blue) and up- (red) regulated genes in primary microglia after 1 h of fAβ treatment versus control. (B) Volcano plot of differentially expressed genes (DEGs) after 12 h of fAβ₄₂ treatment versus control in primary microglial cultures. (C) Volcano plot of DEGs after 12 h of oAβ₄₂ treatment in primary microglial cultures. (D) Volcano plot of DEGs after 12 h of Aβ₄₂ fibrils treatment in primary microglial cultures. (E) Bubble plots of Gene Ontology (GO) category enrichment results for down-regulated genes. (F) Bubble plots of GO category enrichment results for up-regulated genes. Plots for GO category over-enrichment analyses show the top 10 hits for each comparison by enrichment score after a filter step by a *P*-value adjusted for multiple comparisons of ≤0.05 and keeping GO categories with >5 genes within the category.

oA β , 12-h (versus control). The 865 commonly up-regulated genes are enriched with GO terms involved with peptidase and chemokine activity (i.e., threonine-type endopeptidase activity), whereas the 865 commonly down-regulated genes are enriched in terms involving posttranslational modifications (histone demethylase activity and ubiquitin-like protein ligase activity) (Fig S2A and B and Tables S21 and S22). Interestingly, the 170 genes that are up-regulated in oA β , 12-h treatment but down-regulated in fA β , 12-h treatments are involved in cell cycle (i.e., anaphase-promoting complex) and microtubule motor activities (i.e., motor activity and ATP-dependent microtubule motor activity). The 51 genes down-regulated in oA β , 12-h treatment but up-regulated in fA β , 12-h treatment which are involved in antigen binding and immune responses (i.e., TAP complex binding and CD8 receptor binding).

An analysis comparing fA β , 1-h treatment with oA β , 12-h treatment reveals similar results (Fig S2C and D and Tables S23 and S24). Commonly up-regulated genes (515 genes) have roles involving the immune system (RAGE receptor binding and chemokine activity) and kinase activities (MAP kinase tyrosine/threonine phosphatase activity), whereas there was no significant enrichment of GO terms (P -value adjusted for multiple comparisons ≤ 0.1) for the 387 commonly down-regulated genes. The divergently responding 56 genes that are up-regulated in oA β , 12-h treatment but down-regulated in fA β , 1-h treatment are involved in the cell cycle (anaphase-promoting complex binding) and microtubule motor processes (microtubule motor activity), whereas the 78 genes up-regulated in fA β , 1-h treatment, but down-regulated in fA β , 12-h treatment are involved in the innate immune response (complement component C1q complex binding). This analysis highlights the up-regulation of genes involved in the cell cycle and microtubule motor pathways after oA β treatment.

A direct comparison of significant changes in gene expression between acute 1-h versus longer term 12-h fA β treatments expose 515 commonly up-regulated genes involved in cytokine and immune activity (immunoglobulin receptor binding and chemokine receptor binding) and 507 commonly down-regulated genes involved in microtubule motor activity (microtubule binding and microtubule motor activity; Fig S2E and F and Tables S25 and S26). Longer term fA β treatment resulted in up-regulation of 93 genes that are initially down-regulated in 1-h fA β treatment that are involved in adenylation and GTPase activities (adenylyltransferase activity, GTPase activity, and nucleoside-triphosphatase activity). Acute fA β , 1-h treatment triggered an up-regulation of 98 genes that are down-regulated after 12 h of treatment which are enriched in diverse GO terms, including complement component C1q complex binding, DNA helicase activity, and integrin binding.

For a more comprehensive view of these disparate changes in microglia after the application of different A β species, we examined all genes that were identified as a DEG in any of the of the three treatment paradigms versus control and plotted a heat map of their z-scores with hierarchical clustering of the genes (Fig 2). Clear patterns of transcriptional changes can be seen between conditions. To identify the genes within these clusters, we cut the hierarchical tree at a height of 5.75 which resulted in 13 gene clusters that were then analyzed by GO analysis (Fig 2 and Tables 1 and

Figure 2. Hierarchical clustering of differentially expressed genes in A β 42-treated microglia reveals unique gene signatures.

Hierarchical clustering Z-scores of gene expression data. A cut height of $h = 5.75$ was applied to identify clusters of genes with similar expression patterns which produced 13 clusters.

Table 1. Gene ontology (GO) analysis of differentially expressed gene clusters in A β -treated microglia.

Cluster	Control	oA β , 12-h	fA β , 1-h	fA β , 12-h	GO category (molecular function)	Enrichment score	P-value
13	↑	Mix	Mix	Mix	Carbohydrate:proton symporter activity	24.95	9.15×10^{-3}
					JUN kinase activity	22.46	1.02×10^{-2}
					Neurexin family protein binding	17.28	1.32×10^{-2}
12	↑	↓	↓	↑	Kainate selective glutamate receptor activity	5.44	4.14×10^{-2}
					Testosterone dehydrogenase (NAD ⁺) activity	5.44	4.24×10^{-2}
					Alpha-adrenergic receptor activity	5.44	4.26×10^{-2}
4	↑	↓	↑	↓	ATPase inhibitor activity	4.66	3.16×10^{-4}
					RNA polymerase II transcription cofactor binding	3.11	9.28×10^{-3}
					LBD domain binding	2.66	1.26×10^{-2}
10	↑	↓	↓	↓	Histone demethylase activity (H3-K9 specific)	8.02	3.99×10^{-6}
					Leucine binding	8.02	1.64×10^{-3}
					Insulin binding	8.02	2.14×10^{-3}
8	↑	↑	↓	↓	DNA insertion or deletion binding	8.09	1.49×10^{-3}
					MutLalpha complex binding	8.09	1.52×10^{-3}
					sphingosine N-acyltransferase activity	6.94	2.06×10^{-3}
2	↑	↓	↑	↓	3-hydroxyacyl-CoA dehydrogenase activity	2.08	4.12×10^{-3}
					Co-receptor binding	1.85	1.52×10^{-3}
					Dolichyl-phosphate-mannose-protein mannosyltransferase activity	1.85	6.07×10^{-3}
11	~	↓	↑	↓	STAT family protein binding	1.39	7.17×10^{-3}
					Complement component C1q binding	1.39	7.36×10^{-3}
					TAP complex binding	1.24	9.57×10^{-3}
9	↓	~	↑	↓	Stearoyl-CoA 9-desaturase activity	7.39	1.72×10^{-3}
					MAP kinase tyrosine/serine/threonine phosphatase activity	6.83	8.84×10^{-6}
					Acyl-CoA desaturase activity	6.34	2.39×10^{-3}
3	↓	↑	↓	↑	Threonine-type endopeptidase activity	3.25	4.46×10^{-14}
					Threonine-type peptidase activity	3.25	4.46×10^{-14}
					Proteasome-activating ATPase activity	3.25	7.92×10^{-5}
7	↓	↓	mix	↑	TAP binding	6.99	7.76×10^{-10}
					TAP complex binding	6.10	6.10×10^{-7}
					CD8 receptor binding	5.99	4.93×10^{-8}
6	mix	mix	↓	↑	Platelet-derived growth factor binding	6.51	6.36×10^{-7}
					Extracellular matrix structural constituent conferring compression resistance	5.58	1.57×10^{-6}
					Cobalt ion binding	4.69	4.11×10^{-4}
1	~	↑	↓	↓	Single-stranded DNA-dependent ATPase activity	7.97	3.77×10^{-18}
					Kinetochores binding	7.76	3.05×10^{-6}
					Single-stranded DNA-dependent ATP-dependent DNA helicase activity	7.28	2.24×10^{-7}
5	↓	↑	~	~	G protein-coupled adenosine receptor activity	5.31	3.35×10^{-3}
					Structural constituent of presynapse	4.13	5.78×10^{-3}
					Low-density lipoprotein particle receptor activity	3.71	6.96×10^{-3}

GOseq analysis to analyze GO category over-enrichment was applied to these clusters identified in Fig 2. The top three categories are shown after ranking by enrichment score and filtering for genes with a P-value of <0.05 and to remove categories with <5 genes within the category.

S27–S29). Cutting the hierarchical tree at this height identified clusters of genes that were visually apparent. By this analysis, we identified clusters of genes that have similarities in expression patterns after treatment with different A β conformations. For example, genes in cluster 10 are involved in transcriptional processes and have decreased expression in all three conditions compared with controls. However, this analysis also highlights the clusters of genes that have a unique transcriptional signature in response to specific A β conformations. Genes within clusters 11 and 9 have increased expression levels after acute fA β treatment and are enriched in terms involving metabolic processes and immune responses and cell signaling. Genes in cluster 7 are increased after long-term fA β treatment and encompass functions of the antigen processing and the immune system. Genes in clusters 1 and 5 are strongly increased in expression after oA β treatment and are involved in cell cycle and nucleobase metabolism.

Gene network changes in microglia highlight specific transcriptional responses to A β conformations

We applied a weighted gene co-expression network analysis (WGCNA) onto the expression data from A β -treated primary microglial cultures. WGCNA is a method to study biological networks by analyzing pair-wise correlations between the genes within the dataset (Langfelder & Horvath, 2008). We identified 71 co-expression modules (Fig 3 and Tables S30 and S33). We correlated the modules with treatment paradigms (Fig 3A) and annotated these modules using a gene overlap analysis (Shen, 2020) with genes identified with subpopulations of microglial cells identified in prior bulk, single-cell (sc-), single-nuclear (sn-) RNA-seq, or spatial transcriptomic studies (Fig 3B and Table S34). We additionally annotated the modules by KEGG and GO analysis to identify enrichment of pathways within the modules (Fig 3C and Tables S31 and S32). By relating the modules to each treatment condition, we observed interesting patterns in module behavior.

Of these modules, 17 modules are positively correlated with all forms of treatment and indicate a nonspecific response to A β treatment. These modules include antiquewhite4, brown, coral1, darkseagreen4, honeydew1, lavenderblush3, lightcoral, lightcyan, lightcyan1, lightgreen, lightsteelblue1, orangered3, orangered4, saddlebrown, violet, white, and yellow4. GO and KEGG pathway analysis reveals that genes within these modules are involved in a variety of molecular functions previously linked with AD including cytokine and chemokine activities (lightgreen) the proteasome (brown and saddlebrown), the spliceosome (lavenderblush3 and saddlebrown), and neurodegenerative pathways, including AD, Parkinson's disease, and Huntington's disease (brown and saddlebrown). Fifteen modules are negatively correlated with all forms of A β treatment—again, indicating a nonspecific response—and include the black, brown4, darkmagenta, darkolivegreen, floralwhite, greenyellow, magenta, mediumpurple3, midnightblue, navajowhite2, paleturquoise, sienna3, skyblue, skyblue2, steelblue, and yellowgreen modules. The genes within these modules are enriched in genes involved in Rab and Ras GTPase activities (mediumpurple3) and with fatty acid metabolism (darkolivegreen).

Six modules are positively correlated with acute, 1-h fA β treatment and are either negatively correlated or not significantly correlated with the other treatments. These modules characterize the acute response to fA β treatment and include the tan, salmon, skyblue3, maroon, plum2, and cyan modules. These modules represent genes with functions involved with ion channel activities (cyan), histone modification activity (plum2), RNA processing and splicing, and protein ubiquitination and acetylation (skyblue3).

There are five modules that are positively correlated to long-term, 12-h fA β and include the darkslateblue, lightpink4, palevioletred3, blue, and coral2 modules. Genes within these modules are enriched with genes with immune/inflammatory/cytokine functions (blue), RNA binding (darkslateblue), GTPase activity (palevioletred and coral2), and transcriptional regulation (lightpink4). In addition, it is within the blue module that most reactive and responsive microglial markers reside (Fig 3C).

Five other modules are positively correlated with long-term, 12-h oA β treatment and include bisque4, thistle2, mediumorchid, turquoise, and salmon4. These modules are enriched with genes which are involved with extracellular matrix structural components (bisque4) and DNA replication and repair and the cell cycle (turquoise). These analyses further support our original observation that indicates unique microglia transcriptional responses to different species of A β peptides.

Interestingly, subpopulations of microglia previously identified in sc-, sn-RNA-seq, or spatial transcriptomic studies did not fall within any single module (Fig 3B). For example, plaque-induced genes (PIGs) which are found in microglia surrounding A β plaques (Chen et al, 2020) fall across multiple modules and those modules do not fit any pattern of being correlated or not with any treatment paradigm, including being both negatively and positively correlated with various treatments. This pattern also holds for genes found within the neurodegenerative disease-associated phagocytic microglia cells (DAMs) (Keren-Shaul et al, 2017) and microglia associated with a neurodegenerative phenotype (MGnd) (Krasemann et al, 2017). As noted in these prior studies, the microglia subpopulations share a number of genes in common.

To examine the strength of gene–gene connections with these networks, we chose representative modules that were positively correlated in only one treatment type and examined the networks across all treatments (Fig 4). We plotted edge weights to represent gene–gene connection strengths in an ordered heat map to visualize the overall network strength more easily between the various treatment paradigms. Given that the salmon module has the strongest correlation value with the 1-h fA β treatment, we used this as a representative network for acute, 1-h fA β treatment. We find the genes within the salmon module have a stronger overall connection as compared with long-term, 12-h fA β , or oA β treatments (Fig 4A). Similar enhancements in gene–gene network strength were seen for the blue module which is positively correlated with long-term, 12-h fA β treatment (Fig 4B). Although this module does not have the strongest correlation value of the five modules highly correlated with the 12-h fA β treatments, we chose to examine this module as its member genes are enriched in interferon and immune signaling pathways. Finally, the turquoise

Figure 3. Weighted gene correlation network analysis.

Gene modules found by weighted gene co-expression network analysis in A β -treated primary microglia. **(A)** Modules are colored in a heat map by their correlation value with the different A β treatments. Modules with nonsignificant P -values associated or with an absolute correlation value or <0.5 are indicated in gray. **(B)** Bubble plot of a gene overlap analysis to identify shared genes between the module and previously identified microglial subtypes. Modules with significant ($P \leq 0.05$) odds ratios of overlapping genes are colored as in the scale to the right. The number of overlapping genes is indicated by the dot size. **(C)** KEGG pathway over-enrichment analysis for genes within each module. Pathways with an over-represent P -value ≤ 0.05 , the number of module genes within the pathway >5 , and an enrichment score >1.5 are depicted. P -value is indicated by the color score and the enrichment score by the dot size.

module, which has the highest correlation value of the five modules highly correlated with oA β treatment, was chosen as the representative module for positive correlation with long-term, 12-h oA β treatment (Fig 4C). This module also shows a striking increase in

network connection strength as compared with the other two conditions. Genes within this module show enrichment in cell cycle, DNA replication, and repair pathways. The top hub genes for these three modules are listed in Table 2.

Figure 4. Gene networks are strongest in the modules that are positively correlated with A β treatments.

Gene networks are shown as heat maps of the edge weight. A greater edge weight (darker blue shades) indicates a strong gene–gene connection. The order of genes within each heat map is preserved for the comparisons across A β treatment types. **(A)** The gene network for the salmon module, a representative module positively correlated with acute, 1-h fA β treatment, is strongest than in 12-h fA β or 12-h oA β treatments. **(B)** The gene network for the blue module, a representative module positively correlated with long-term, 12-h fA β treatment is stronger than in 1-h fA β or 12-h oA β conditions. **(C)** The gene network for the turquoise modules, which represent a module positively correlated with long-term, 12-h oA β treatment, is strongest in oA β treatments.

Transcriptional changes in primary microglia do not mimic those seen in the transgenic CRND8 mouse brain

To understand how well ex vivo changes in primary microglia cultures recapitulate in vivo processes, we examined transcriptional changes in the brains of transgenic amyloid mouse model CRND8 at 3, 6, 12, and 20 mo of age by bulk RNA-seq. Using the same cutoff values to identify DEGs as above, we find that at 3 mo of age there are few transcriptional changes between the

transgenic CRND8 and their nontransgenic littermate controls (11 up-regulated and 4 down-regulated, Fig 5A and Table S35). By 6 mo of age, the number of transcriptional changes increases to 187 up-regulated and 105 down-regulated genes (Fig 5B and Table S40). At 12 mo of age, the number of DEGs is higher than at previous time points and is dominated by changes in up-regulated genes (493 up-regulated genes) over those that are down-regulated (103 down-regulated genes, Fig 5C and Table S45). At 20 mo, more genes continue to be up-regulated (746

Table 2. Weighted gene co-expression network analysis module statistics.

Hub gene	Gene significance	Gene significance <i>P</i> -value	Module membership	Module membership <i>P</i> -value	kWithin
Salmon	to fAβ ₄₂ , 1-h				
Gabbr2	0.9984	8.34×10^{-14}	0.9854	5.17×10^{-9}	167.213
Vegfa	0.9980	2.47×10^{-13}	0.9927	1.58×10^{-10}	166.033
Cyth1	0.9977	4.60×10^{-13}	0.9953	1.79×10^{-11}	164.974
Rab7b	0.9976	5.71×10^{-13}	0.9903	6.51×10^{-10}	159.731
Tnfrsf21	0.9971	1.72×10^{-12}	0.9929	1.42×10^{-10}	164.391
Gpcpd1	0.9965	3.83×10^{-12}	0.9920	2.47×10^{-10}	157.545
Usp2	0.9962	6.38×10^{-12}	0.9498	2.32×10^{-6}	155.563
Folr2	0.9961	6.94×10^{-12}	0.9800	2.46×10^{-8}	167.461
Picalm	0.9961	7.20×10^{-12}	0.9726	1.16×10^{-7}	159.591
Plek	0.9959	8.80×10^{-12}	0.9896	9.34×10^{-10}	159.217
Blue	to fAβ ₄₂ , 12-h				
Tmem176a	0.9997	3.13×10^{-17}	0.9513	1.98×10^{-6}	468.954
Acp2	0.9996	4.65×10^{-17}	0.9321	1.02×10^{-5}	462.765
Gpr18	0.9996	5.40×10^{-17}	0.9432	4.24×10^{-6}	450.890
Fnbp1l	0.9995	1.77×10^{-16}	0.9736	9.61×10^{-8}	452.921
Tmem176b	0.9995	2.50×10^{-16}	0.9316	1.05×10^{-5}	479.564
Adgre1	0.9994	5.13×10^{-16}	0.9676	2.65×10^{-7}	485.170
Slc11a2	0.9994	5.51×10^{-16}	0.9240	1.76×10^{-5}	487.036
Cep85	0.9991	5.73×10^{-15}	0.9440	3.94×10^{-6}	463.008
Cd82	0.9989	1.12×10^{-14}	0.9493	2.43×10^{-6}	462.487
Nr1h3	0.9989	1.34×10^{-14}	0.9719	1.33×10^{-7}	466.064
Turquoise	to oAβ ₄₂ , 12-h				
Asf1b	0.9998	6.09×10^{-19}	0.991	3.71×10^{-10}	400.289
Alox5	0.9998	2.49×10^{-18}	0.933	9.27×10^{-6}	402.563
S100a4	0.9998	3.79×10^{-18}	0.973	1.18×10^{-7}	400.107
Klf2	0.9996	4.53×10^{-17}	0.952	1.89×10^{-6}	402.789
Hal	0.9996	7.56×10^{-17}	0.868	2.49×10^{-4}	401.621
Top2a	0.9996	7.82×10^{-17}	0.996	6.24×10^{-12}	401.975
Cks1b	0.9996	8.13×10^{-17}	0.950	2.16×10^{-6}	403.304
Pygl	0.9991	3.81×10^{-15}	0.961	6.31×10^{-7}	403.646
E2f1	0.9991	5.78×10^{-15}	0.965	3.66×10^{-7}	402.021
Mcm7	0.9989	1.35×10^{-14}	0.958	9.81×10^{-7}	400.930

Top 10 hub genes within the modules depicted in Fig 3 identified by weighted gene co-expression network analysis. Results are sorted by gene significance to each treatment type. Module statistics including gene significance *P* value (to treatment), *P*-values corresponding to the gene significance (*P*-value), module membership value (of gene to module), module membership *P*-value, and gene connectivity within the module (kWithin) are shown.

genes) than down-regulated (115 genes, Fig 5D and Table S50). Trends for GO term enrichment in down-regulated genes was not evident until 12 mo with enriched terms including a variety of receptor binding activities (i.e., glucocorticoid receptor binding and steroid hormone receptor activity) and involvement of core promoter activity (core promoter sequence-specific DNA binding; Fig 5E and Tables S37, S39, S42, S44, S47, S49, S52, and S54). Up-regulated genes are enriched primarily with immune responses (immunoglobulin receptor activity and IgG binding) that are

consistent as the mice age (Fig 5F and Tables S36, S38, S41, S43, S46, S48, S51, and S53).

Not surprisingly, direct comparisons of the microglial-specific genes in Aβ-treated primary microglia with transgenic CRND8 mice are poorly correlated (Figs 6 and S3). Correlation values are low between differentially expressed microglial genes in transgenic CRND8 mice at 20 mo versus Aβ-treated primary microglia for any treatment paradigm, oAβ 12-h (Fig 6A), fAβ 12-h (Fig S3A), or fAβ 1-h (Fig S3B). In the transgenic CRND8, these genes are nearly

Figure 5. Differential gene expression in transgenic CRND8 mice.

(A) Total changes in down- (blue) and up- (red) regulated genes in transgenic CRND8 mouse brains versus nontransgenic controls at 3 mo. (B) Total changes in down- and up-regulated genes in transgenic CRND8 mouse brains versus nontransgenic controls at 6 mo. (C) Total changes in down- and up-regulated genes in transgenic CRND8 mouse brains versus nontransgenic controls at 12 mo. (D) Total changes in down- and up-regulated genes in transgenic CRND8 mouse brains versus nontransgenic controls at 20 mo. (E) Bubble plots of Gene Ontology (GO) category enrichment results for down-regulated genes. (F) Bubble plots of GO category enrichment results for up-regulated genes. Plots for GO category over-enrichment analysis show the top 10 hits for each comparison by enrichment score after a filter step by a *P*-value adjusted for multiple comparisons of ≤ 0.1 and keeping GO categories with >5 genes within the category.

Figure 6. Microglia transcriptional responses at the individual gene level are not reflective of changes seen in the CRND8 model. (A, B) Comparisons of log₂ fold change values for microglial genes (Zhang et al, 2014) in transgenic CRND8 versus oAβ treatment in primary microglia show little correlation. Geometric means of FPKM data of representative genes differentially expressed in Aβ-treated primary microglia is shown for Aβ-treated microglia (top row) and CRND8 mouse brains (bottom row) (B). (C, D, E, F) Similar plots are shown for representative differentially expressed genes identified in CRND8 mice (C), Alzheimer's disease-relevant genes (D), representative cytokine genes (E), and representative cytokine receptor genes (F).

universally up-regulated, but are both up- and down-regulated in the primary microglia. We examined representative genes that are highly differentially expressed in Aβ-treated microglia (Fig 6B) which reveal little (*Vim*) to no (*Sod2*, *Sgk1*) corresponding changes in the transgenic CRND8 mice over time—indeed some changes were opposite of those observed in CRND8 (*Fcgr2b*). Conversely, examining a selection of genes that are consistently and significantly changed in transgenic CRND8 mice over time (Fig 6C; *Cst7*, *Irf8*, and *Plek*) exposes variable responses in microglia after the application of either fAβ or oAβ peptide. In addition, a panel of Alzheimer's-disease relevant genes, which are consistently up-

regulated in the transgenic CRND8 mouse brain over time, also reveals variable (*Abi3* versus *Plcg2*)—and sometimes unexpected (*Trem2*)—responses to Aβ peptides in microglia (Fig 6D). This pattern is also seen in a selection of cytokines (Fig 6E; *Ccl3*, *Ccl4* and *Tnf*) and cytokine receptor (Fig 6F; *Ccr5*, *Csf3r*, and *Tnfrsf1a*) genes.

We then examined the transcriptional profile of microglial cell subsets that have been identified in past sc-, sn-RNA-seq, or spatial transcriptomic studies of microglia (Fig 7). As evidenced by the increase in the transgenic CRND8 brains, the expression of these genes within the subpopulations is increased in AD. A general

Figure 7. Microglia subtype transcriptional signatures in primary microglia do not reflect changes seen in the CRND8 model.

Gene signatures for microglia genes and sub-populations of microglia are shown for primary microglia cultures (left) and CRND8 mouse brains (right). (A) Microglia expression signature identified in Zhang et al (2014). (B) Activated microglia expression signature in Aβ-treated microglia. (B) Homeostatic (H2M) microglial gene expression signature as in Sala Frigerio et al (2019). (C) Cycling and proliferating microglia gene expression signature as in Sala Frigerio et al (2019). (D) Interferon-responsive microglia gene expression signature as in Sala Frigerio et al (2019). (E) Disease-associated microglia gene expression signature identified in Keren-Shaul et al (2017). (F) Activated response microglia gene expression signature as in Sala Frigerio et al (2019). (G) Plaque-induced microglia gene expression signature as in Chen et al (2020). (H) Neurodegenerative microglia phenotype (MGnD) gene expression signature as in Krasemann et al (2017). **P*-adj < 0.05; ***P*-adj < 0.01; ****P*-adj < 0.001. FPKM, fragments per kilobase per million mapped fragments.

transcriptomic signature of microglial-enriched genes (Zhang et al, 2014) is increased after all A β treatments in microglia primary cultures—a signal that mimics increases seen in transgenic CRND8 mice over time (Fig 7A). A homeostatic microglia (H2M) signature (Sala Frigerio et al, 2019) increases over time in transgenic CRND8 mice, but this increase is seen only in microglial cultures treated for 12-h fA β (Fig 7B). We examined the transcriptional signature associated with cycling and proliferative microglia (Sala Frigerio et al, 2019) (Fig 7C). There is a large increase in the cycling and proliferating microglia signature in oA β -treated microglia, but no difference is seen in the transgenic CRND8—which stands as a contrast to the general trend in the other microglial subtypes. This likely reflects that this population represents a very small percentage of microglial cells within the brain (Sala Frigerio et al, 2019), and its signature is lost within the larger milieu of other cell types within the brain. We also examine interferon-responsive microglia (Fig 7D) (Sala Frigerio et al, 2019). This transcriptional signature increased over time in transgenic CRND8 but a large change is seen only in response to long-term fA β treatment. Interestingly, an increased transcriptional response in the disease associated microglia profile (DAMs, found in the microglia surrounding A β plaques [Keren-Shaul et al, 2017]) is seen in response to fA β , but not oA β treatment, whereas a steady increase is seen in the transgenic CRND8 (Fig 7E). Intriguingly, transcriptional responses linked to both activated response microglia (Fig 7F [Sala Frigerio et al, 2019], which are responsive to A β deposition) and PIGs (Fig 7G [Chen et al, 2020]) are decreased or unchanged in all treatment paradigms in primary microglia while these genes steadily increase over time in transgenic CRND8. In contrast, genes linked to the microglial neurodegenerative phenotype (MGnD, Fig 7H) (Krasemann et al, 2017) appear as a likely reliable indicator of transcriptional changes for all A β treatment paradigms as well as in transgenic CRND8 brains.

Discussion

Acute exposure of cultured primary microglia to oA β or fA β elicits a robust and rapid transcriptional response. Both forms of A β induce significant increases and decreases in RNA levels for hundreds of genes. Nevertheless, transcriptomic responses to oA β and fA β at 12-h are distinguishable. Of note, the finding that oA β increases RNAs associated primarily with cell cycle, whereas fA β increases RNAs associated primarily with phagocytic processes is intriguing.

As there are numerous validated and candidate A β receptors expressed on microglia (Jarosz-Griffiths et al, 2016), such studies indicate that acute exposure to A β aggregates induces robust cellular events that can be assessed at the systems level using transcriptomic approaches. Based on the studies of fA β there is a clear temporality to the response with varying clusters of genes changing in both similar and different directions at the various time points. These data are reminiscent of studies examining acute effects of LPS on primary microglia, although given numerous experimental differences with historical datasets a much more systematic, side by side, comparison would be needed to evaluate the overall similarity in response to classic proinflammatory mediators such as LPS and A β .

As we and others have used primary microglia to study uptake and clearance of A β and A β aggregates, a primary objective of this study was to determine if the response to A β in such acute studies is indicative of system levels changes in mouse models of A β deposition, where A β accumulates over time. In this case, we have compared the transcriptomic changes in CRND8 transgenic model (compared with nontransgenic controls) with our acute transcriptomic signatures of the primary microglia exposed to A β . These data reveal that acute transcriptional responses of primary microglia to A β poorly reflect the in vivo responses of genes to chronic progressive A β accumulation. Like a number of other recent studies, these data suggest that although primary microglial studies may have utility in some settings, extrapolating results from these studies to the in vivo setting is problematic.

Many laboratories in the field, including our own, have focused on responses of microglia to classic cytokines including but not limited to TNF α , IL1 α , IL1 β , IL10, IL6, and IFN γ (Chakrabarty et al, 2010, 2011, 2015; Colon-Perez et al, 2019; Webers et al, 2020). Although these cytokines show massive changes in transcript in primary culture, in vivo transcript levels in the brain are very low throughout the lifespan of the non-Tg and Tg mice. Although some cytokines show small increases over time in the presence of amyloid deposition, the magnitude of this increase is nowhere near the scale of increase observed in the primary culture. The massive increases in transcript levels observed in primary microglial cultures of many of these cytokines and other immune factors have likely contributed to the field's focus on these as key mediators of the microglial responses to A β and other insults. However, data presented here, as well as other studies (Butovsky et al, 2014), highlight differences between the ex vivo and in vivo microglial responses and indicate that the focus on some of these cytokine and other immune factors may be misleading.

Notably, microglia—at least at the transcript level—express moderate to high levels of many classic cytokine receptors in vivo. Perhaps, the low level of ligand expression compared with relatively high levels of receptor would suggest that these receptors on microglia serve primarily to sense non-CNS changes in the cytokine levels after peripheral insults. In any case, these data along with numerous other studies demonstrating the heterogeneity of microglia in vivo (Butovsky et al, 2014; Keren-Shaul et al, 2017; Krasemann et al, 2017; Friedman et al, 2018; Hammond et al, 2019; Chen et al, 2020; Olah et al, 2020) highlight the notion that primary isolated microglia cells are poor proxies for in vivo responses. As study of microglial cells in the brain has many limitations, additional efforts to develop better ex vivo models of microglial responses would benefit the field. Although several reports of such efforts exist (Arber et al, 2017; Croft et al, 2019), further evaluation and “stress-testing” of these and other ex vivo methods will be needed before they are likely to be widely adopted.

Previous studies have focused on the functional consequences of treating various primary CNS cells with oA β or fA β . oA β species have been conceptualized by some in the field as the proximal neurotoxin in AD (Haass & Selkoe, 2007; Wang et al, 2016; Cline et al, 2018; Li & Selkoe, 2020), as they disrupt synaptic transmission in neurons at very low, picomolar concentrations (Waters, 2010; Rammes et al, 2011). However, the evidence that oA β species are overtly toxic with respect to inducing neuronal death is lacking;

further there is debate as to whether appreciable concentrations of intrinsically soluble oligomers exists in the AD brain or mouse models of amyloid deposition (Tseng et al, 1999; Jan et al, 2008, 2011; van Helmond et al, 2010). In contrast, at least in primary neuronal cultures, higher concentrations of various aggregates have been linked to induction of neuronal death via apoptotic mechanisms (Deshpande et al, 2006). Both direct toxicity of the aggregates or aggregate growth and indirect toxicity via activation of glial cells that results in neurotoxicity have been invoked as mechanisms underlying A β induced neuronal death (Kayed & Lasagna-Reeves, 2013). Clearly, the massive alterations in microglial cells observed here in response to synthetic A β aggregates reinforces the potential for neurotoxicity in mixed primary cultures. However, we would note that both oA β and fA β induce massive changes in the transcriptome of microglia and certainly lend little credence to claims by some in the field that fA β is inert (reviewed in Walsh and Selkoe [2007]). Indeed, our results suggest that microglial transcriptional responses to fA β more closely mimic *in vivo* responses to amyloid accumulation as evidenced by the behavior of the “blue” module genes in our study which positively correlated with fA β treatment are paralleled in the transgenic CRND8 brain and the microglial subtype analysis.

As suggested above, the concept that microglial cells might make exquisitely sensitive biosensors that can be used to distinguish between various aggregate forms is intriguing. Microglia do appear at the transcript level to respond in partially overlapping, but distinct ways to oA β or fA β . Much more extensive studies will be needed to follow up on this intriguing observation. However, from a teleological point of view this concept makes quite a bit of sense. Microglial cells with a plethora of damage associated and pathogen associated receptors are designed to respond rapidly to potentially harmful proteins and other stimuli (Deshpande et al, 2006). One would predict that overlapping but distinct binding interactions could result in partially overlapping but distinct responses that might essentially provide a type of integration of signals to distinguish various aggregates.

As the main goal of these studies was to assess the system level responses of microglial cells in culture to A β aggregates and compare that to a longitudinal transcriptomic study in amyloid precursor protein (APP) mice, there are a number of limitations that are worth noting. First, preparations of oligomeric and fibrillar forms of A β were not purified; however, the method of preparation is one that is typically used in many laboratories and each preparation have distinctive features that evident on Western blotting. In addition, these preparations elicit distinct transcriptional responses as outlined in this study. Second, both dose response and more extended time courses were not conducted. Third, we did not include monomeric A β ₄₂, as it would likely aggregate at these concentrations during incubation; nor did we include a short-term oA β ₄₂ time point. Finally, we have not pursued studies to determine whether fA β and oA β induce different functional states in the cultured microglia cells. It is almost certain such studies would yield interesting data, but it is unlikely that it would alter the relevance of the work with respect to disease implications in AD.

A recent elegant study exploring *in vivo* microglial responses to LPS using translational profiling approaches to assess both

ribosome-associated transcripts and proteins showed major discrepancies between the proinflammatory transcriptomic signature and a more immune modulatory and homeostatic protein signature (Boutej et al, 2017). Given the massive up-regulation of proinflammatory transcripts in cultured microglia exposed to A β and the large number of up-regulated microglial transcripts in APP mouse models and human AD, it will be important to integrate proteomic and transcriptomic studies of microglia in the future. Indeed, at least in the Boutej study, the biologic inferences derived from evaluating the proteome or transcriptome are disparate and only when the two are compared directly does the concept of widespread translation repression emerge. Additional studies also show that even the process of rapid isolation of microglial cells from the brain changes their transcriptome (Tham et al, 2003; Lin et al, 2017; He et al, 2018). Thus, even though single-cell transcriptomic and proteomic studies of isolated microglia cells potentially provide new insights into their roles in health and disease, additional validation using *in situ* methodologies is needed to confirm that changes observed reflect changes *in situ* and are not induced during the isolation.

The number of studies focusing on microglia cells and their impact on AD and other neurodegenerative disorders is rapidly expanding. This study and many others highlight that traditional methods to study them, such as in primary cultures, are highly artificial and may lead to inappropriate conclusions. Current efforts to develop strategies to harness microglial function in a therapeutically beneficial fashion must by necessity study the effect of that therapy *in vivo*. However, given the large number of immune factors that are emerging as modulators of neurodegenerative pathologies, and the limitations of only studying these cells *in vivo*, additional efforts to validate *ex vivo* systems that better approximate microglial functions *in vivo* were warranted.

Materials and Methods

Animal research

All animal research was performed under protocols approved by the Institute for Animal Care and Use Committee at the University of Florida.

Microglial primary cultures and A β ₄₂ treatment

Mouse pups for primary microglial cultures are obtained from matings of B6/C3HF1 mice (Envigo). Mice are given *ad libitum* access to food and water and are maintained on a 12-h light/12-h dark cycle. Primary microglia cultures were isolated following described protocols (Rosario et al, 2016). Briefly, cortices were isolated at postnatal day P2-P3. The mixed microglial/astrocyte cultures were maintained in 75-cm² flasks with 20 ml of DMEM containing 10% fetal bovine serum. After 10 d, the flasks were shaken on a rotary platform for 30 min at 37°C at 150 rpm to dislodge the microglia from the adherent astrocyte layer. The microglia were plated into six-well plates and maintained at 37°C. 1 d after plating, microglia were treated with 5 μ M A β ₄₂ fibrils or oligomers for 1- or 12 h as

noted. Cells were washed with PBS before harvest. Three replicates for each condition were performed.

Fibrillar and oligomeric A β preparation

Fibrillar and oligomeric forms of A β were prepared as previously described (Stine et al, 2003; Chakrabarty et al, 2018). Aliquots (10, 100, and 1,000 ng) were separated on SDS-PAGE page run using Biorad Criterion 10% bis-tris gel and XT running buffer/sample buffer for 60 m at 180 V (constant). Gel transferred onto 0.2-micron PVDF in Towbin transfer buffer for 45 m at 150 V (constant). 6E10 (BioLegend) primary antibody diluted at 1:1,000 and applied for 1.5 h at 37°. Primary antibody was detected with goat anti-mouse IR700 and scanned on LiCor Odyssey 700 mm channel.

RNA extraction and sequencing

Microglial RNA was extracted using the RNeasy mini extraction kit with on-column DNase treatment (QIAGEN). RNA quality was determined with the Qubit RNA HS assay. RNA quality was checked via RIN on an Agilent Bioanalyzer 2100 with the Eukaryote Total RNA Nano chip. Libraries were generated with the Illumina RNA-seq library prep for low input RNA. Libraries were sequenced on paired-end, 75 bp runs on the Nextseq 500 (Illumina). RNA QC, library preparation, and sequencing were performed at the University of Florida's Interdisciplinary Center for Biotechnology Research sequencing core.

Transgenic CRND8 RNA-sequencing data

Data for the transgenic CRND8 mice were obtained from the AMP-AD Knowledge Portal (doi: 10.7303/syn3157182). Experimental details are located within the data portal's Web site. BAM files were downloaded from the AD Knowledge portal and used with the analysis method described below. Animal numbers are as follows: 3-mo, nTg-F: 6; 3-mo, nTg-M: 6; 3-mo, Tg-F: 6; 3-mo, Tg-M: 6; 6-mo, nTg-F: 5; 6-mo, nTg-M: 7; 6-mo, Tg-F: 5; 6-mo, Tg-M: 6; 12-mo, nTg-F: 5; 12-mo, nTg-M: 5; 12-mo, Tg-F: 7; 12-mo, Tg-M: 7; 20-mo, nTg-F: 11; 20-mo, nTg-M: 5; 20-mo, Tg-F: 5; and 20-mo, Tg-M: 3. Male and female mice of the same age and genotype were grouped together for this analysis.

RNA-seq analysis

FASTQ alignment, gene counts, and differential expression analysis

Resulting FASTQ files were aligned against the mouse genome (GRCm38) and GRCm38.94 annotation using STAR v2.6.1a (Dobin et al, 2013) to generate BAM files. BAM files were used to generate gene counts were generated using Rsamtools (Morgan et al, 2018) and the summarizeOverlaps function with the GenomicAlignments package (Lawrence et al, 2013). Differential gene expression analysis was performed with DESeq2 package using the "DESeq" function with default settings (Love et al, 2014) which fits a generalized linear model for each gene. Subsequent Wald test *P*-values are adjusted for multiple comparisons using the Benjamini-Hochberg method (adjusted *P*-value). Pair-wise changes in gene expression levels were examined between groups to identify DEGs. DEGs were defined as an absolute log₂ fold change ≥ 0.5 and an adjusted *P*-value ≤ 0.05 .

WGCNA

The WGCNA package in R (Langfelder & Horvath, 2008, 2012) was used to construct gene correlation networks from the expression data after filtering and removing genes with zero variance. For the microglia dataset, a soft power setting of nine was chosen using the "pickSoftThreshold" function within the WGCNA package. The network was constructed using all microglial samples. Adjacency matrices were constructed using expression data and this power setting with the "adjacency" function and a signed hybrid network. Module identification was performed using the "cutreeDynamic" function and a deepSplit setting of two with a minimum module size of 30 for all analyses.

Functional annotation of DEGs, heat map clusters, and WGCNA modules

Gene ontology enrichment analysis was performed with goseq v1.42.0 (Young et al, 2010) to identify gene ontology categories—focusing on the molecular function category—and KEGG pathways that are affected between the various conditions. For DEGs, up- and down-regulated gene lists were analyzed separately. For WGCNA, gene lists from each module were used as input. Over-represented *P*-values were adjusted for multiple comparisons using the Benjamini-Hochberg adjustments for controlling false-discovery rates. An enrichment score was calculated by an observed-over-expected ratio of

$$(DEG/totalDEG)/(CategoryTotal/GeneTotal),$$

where *DEG* represents the total number of DEGs or module genes within the GO or KEGG category, *totalDEG* represents the total number of DEGs or module genes; *CategoryTotal* represents the total number of genes within the GO or KEGG category, and *GeneTotal* represents the total number of genes examined. GO terms and KEGG pathways are filtered for *P*-values adjusted for multiple comparisons (BHadjust) < 0.05 (A β -treated microglia) or 0.1 (CRND8 mice), enrichment scores > 1 , and total number of genes within the category > 5 .

Z-scores for genes identified as a DEG for any A β -treatment comparison versus control were plotted in a heat map using pheatmap v1.0.12. Clusters were identified using the cutree function with $h = 5.75$. goseq was used for GO and KEGG pathway analysis on genes within each cluster. GO terms and KEGG pathways are filtered for *P*-values < 0.05 , enrichment scores > 1 , and total number of genes within the category > 5 .

Gene lists to annotate WGCNA modules and identify microglia subtype signatures were identified from previously published studies (Zhang et al, 2014; Keren-Shaul et al, 2017; Krasemann et al, 2017; Friedman et al, 2018; Hammond et al, 2019; Sala Frigerio et al, 2019; Chen et al, 2020) (see also Table S33). Gene overlap analysis was conducted with the GeneOverlap package in R (Shen, 2020). GeneOverlap uses Fisher's exact test to calculate the *P*-value for significance testing and calculating the odds ratio. goseq was used for GO and KEGG pathway analysis of genes within each module filtering for those terms with *P*-values < 0.05 , enrichment scores > 1 , and total number of genes within the category > 5 .

Direct comparisons of DEGs between treatment types

DEG datasets for each treatment paradigm against control were filtered for significant gene changes using criteria described above. The distribution of resulting $\log_2$ fold change was tested for a normal distribution using the Shapiro–Wilk normality test. The correlation value for the $\log_2$ fold change value in each pair-wise comparison was calculated using Spearman’s rank-order correlation test at a confidence level set to 0.95 in R and graphs were drawn using the ggpubr package in R (Kassambara, 2020).

Statistical analysis and data visualizations

ANOVA with Tukey’s post hoc multiple comparisons test was performed in R. Data visualizations were generated in R using the ggplot2 package (Wickham, 2016) unless otherwise noted. Bar plots show mean $\pm$ SD. For boxplots, upper, middle, and lower hinges correspond to first quartile, median, and third quartiles, respectively. Upper (or lower) whiskers correspond to the largest (or smallest) observation beyond the upper hinge up to 1.5 times the interquartile range. Outliers beyond the upper and lower whiskers are plotted independently.

Data Availability

FASTQ files for the A β -treated primary microglia samples are available via the AD Knowledge Portal (<https://adknowledgeportal.org>). The AD Knowledge Portal is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership (AMP-AD) Target Discovery Program and other National Institute on Aging-supported programs to enable open-science practices and accelerate translational learning. The data, analyses, and tools are shared early in the research cycle without a publication embargo on secondary use. Data are available for general research use according to the following requirements for data access and data attribution (<https://adknowledgeportal.org/DataAccess/Instructions>).

For access to content described in this manuscript, see: <http://doi.org/10.7303/syn25006578>. Interactive data portals are available for viewing at the following: A β -treated microglial DEG data: <https://tinyurl.com/y3q3kaoe>. CRND8 DEG data: <https://tinyurl.com/y5ewkuw> cross-treatment comparisons of DEG data: <https://tinyurl.com/yyph68vc>.

Supplementary Information

Supplementary Information is available at <https://doi.org/10.26508/lsa.202101108>.

Acknowledgements

Support for these studies was provided by the National Institutes of Health National Institute on Aging U01 AG046139, P30 AG066506, P50 AG047266. N Ertekin-Taner is also funded in part by National Institutes of Health National Institute on Aging RF1 AG051504, and R01 AG061796.

Author Contributions

KN McFarland: data curation, formal analysis, investigation, visualization, methodology, and writing—original draft, review, and editing.
C Ceballos: investigation and methodology.
A Rosario: investigation and methodology.
TB Ladd: investigation and methodology.
BD Moore: investigation, methodology, and writing—review and editing.
G Golde: visualization.
X Wang: resources.
M Allen: resources.
N Ertekin-Taner: resources.
CC Funk: methodology.
M Robinson: methodology.
P Baloni: methodology.
N Rappaport: methodology.
P Chakrabarty: conceptualization, investigation, and methodology.
TE Golde: conceptualization, resources, supervision, funding acquisition, project administration, and writing—original draft, review, and editing.

Conflict of Interest Statement

TE Golde is a cofounder of Lacerta Therapeutics and Andante Biologics Inc.

References

- Aguzzi A, Barres BA, Bennett ML (2013) Microglia: Scapegoat, saboteur, or something else? *Science* 339: 156–161. doi:[10.1126/science.1227901](https://doi.org/10.1126/science.1227901)
- Arber C, Lovejoy C, Wray S (2017) Stem cell models of Alzheimer’s disease: Progress and challenges. *Alzheimers Res Ther* 9: 42. doi:[10.1186/s13195-017-0268-4](https://doi.org/10.1186/s13195-017-0268-4)
- Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. *N Engl J Med* 367: 795–804. doi:[10.1056/NEJMoa1202753](https://doi.org/10.1056/NEJMoa1202753)
- Bellenguez C, Charbonnier C, Grenier-Boley B, Quenez O, Le Guennec K, Nicolas G, Chauhan G, Wallon D, Rousseau S, Richard AC, et al (2017) Contribution to Alzheimer’s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. *Neurobiol Aging* 59: 220–220.e9. doi:[10.1016/j.neurobiolaging.2017.07.001](https://doi.org/10.1016/j.neurobiolaging.2017.07.001)
- Bennett ML, Bennett FC, Liddelaw SA, Ajami B, Zamanian JL, Fernhoff NB, Mulinyawe SB, Bohlen CJ, Adil A, Tucker A, et al (2016) New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci U S A* 113: E1738–E1746. doi:[10.1073/pnas.1525528113](https://doi.org/10.1073/pnas.1525528113)
- Boutej H, Rahimian R, Thammisetty SS, Béland LC, Lalancette-Hébert M, Kriz J (2017) Diverging mRNA and protein networks in activated microglia reveal SRSF3 suppresses translation of highly upregulated innate immune transcripts. *Cell Rep* 21: 3220–3233. doi:[10.1016/j.celrep.2017.11.058](https://doi.org/10.1016/j.celrep.2017.11.058)
- Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglspenger T, Dake B, Wu PM, Doykan CE, et al (2014) Identification of a unique TGF- β -dependent molecular and functional signature in microglia. *Nat Neurosci* 17: 131–143. doi:[10.1038/nn.3599](https://doi.org/10.1038/nn.3599)
- Carrasquillo MM, Allen M, Burgess JD, Wang X, Strickland SL, Aryal S, Siuda J, Kachadoorian ML, Medway C, Younkin CS, et al (2017) A candidate

- regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. *Alzheimers Dement* 13: 663–673. doi:[10.1016/j.jalz.2016.10.005](https://doi.org/10.1016/j.jalz.2016.10.005)
- Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P (2010) IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. *J Immunol* 184: 5333–5343. doi:[10.4049/jimmunol.0903382](https://doi.org/10.4049/jimmunol.0903382)
- Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE (2011) Hippocampal expression of murine TNF α results in attenuation of amyloid deposition in vivo. *Mol Neurodegener* 6: 16. doi:[10.1186/1750-1326-6-16](https://doi.org/10.1186/1750-1326-6-16)
- Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, et al (2015) IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. *Neuron* 85: 519–533. doi:[10.1016/j.neuron.2014.11.020](https://doi.org/10.1016/j.neuron.2014.11.020)
- Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, Funk CC, Cruz PE, Allen M, Yaroshenko M, et al (2018) TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. *J Exp Med* 215: 2247–2264. doi:[10.1084/jem.20180484](https://doi.org/10.1084/jem.20180484)
- Chen WT, Lu A, Craessaerts K, Pavie B, Sala Frigerio C, Corthout N, Qian X, Laláková J, Kühnemund M, Voytyuk I, et al (2020) Spatial transcriptomics and in situ sequencing to study Alzheimer's disease. *Cell* 182: 976–991.e19. doi:[10.1016/j.cell.2020.06.038](https://doi.org/10.1016/j.cell.2020.06.038)
- Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, French J, et al (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. *J Biol Chem* 276: 21562–21570. doi:[10.1074/jbc.M100710200](https://doi.org/10.1074/jbc.M100710200)
- Cline EN, Bicca MA, Viola KL, Klein WL (2018) The amyloid- β oligomer hypothesis: Beginning of the third decade. *J Alzheimers Dis* 64: S567–S610. doi:[10.3233/JAD-179941](https://doi.org/10.3233/JAD-179941)
- Colon-Perez LM, Ibanez KR, Suarez M, Torroella K, Acuna K, Ofori E, Levites Y, Vaillancourt DE, Golde TE, Chakrabarty P, et al (2019) Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis. *Neuroimage* 202: 116138. doi:[10.1016/j.neuroimage.2019.116138](https://doi.org/10.1016/j.neuroimage.2019.116138)
- Conway OJ, Carrasquillo MM, Wang X, Bredenberg JM, Reddy JS, Strickland SL, Younkin CS, Burgess JD, Allen M, Lincoln SJ, et al (2018) ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. *Mol Neurodegener* 13: 53. doi:[10.1186/s13024-018-0289-x](https://doi.org/10.1186/s13024-018-0289-x)
- Croft CL, Futch HS, Moore BD, Golde TE (2019) Organotypic brain slice cultures to model neurodegenerative proteinopathies. *Mol Neurodegener* 14: 45. doi:[10.1186/s13024-019-0346-0](https://doi.org/10.1186/s13024-019-0346-0)
- Cummings J (2019) The National Institute on Aging-Alzheimer's Association framework on Alzheimer's disease: Application to clinical trials. *Alzheimers Dement* 15: 172–178. doi:[10.1016/j.jalz.2018.05.006](https://doi.org/10.1016/j.jalz.2018.05.006)
- Deshpande A, Mina E, Glabe C, Busciglio J (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. *J Neurosci* 26: 6011–6018. doi:[10.1523/JNEUROSCI.1189-06.2006](https://doi.org/10.1523/JNEUROSCI.1189-06.2006)
- Dewapriya P, Himaya SW, Li YX, Kim SK (2013) Tyrosol exerts a protective effect against dopaminergic neuronal cell death in in vitro model of Parkinson's disease. *Food Chem* 141: 1147–1157. doi:[10.1016/j.foodchem.2013.04.004](https://doi.org/10.1016/j.foodchem.2013.04.004)
- Dickson DW (1997) The pathogenesis of senile plaques. *J Neuropathol Exp Neurol* 56: 321–339. doi:[10.1097/00005072-199704000-00001](https://doi.org/10.1097/00005072-199704000-00001)
- Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH (1988) Alzheimer's disease: A double-labeling immunohistochemical study of senile plaques. *Am J Pathol* 132: 86–101.
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* 29: 15–21. doi:[10.1093/bioinformatics/bts635](https://doi.org/10.1093/bioinformatics/bts635)
- Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, et al (2018) Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models. *Cell Rep* 22: 832–847. doi:[10.1016/j.celrep.2017.12.066](https://doi.org/10.1016/j.celrep.2017.12.066)
- Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al (2013) TREM2 variants in Alzheimer's disease. *N Engl J Med* 368: 117–127. doi:[10.1056/NEJMoa1211851](https://doi.org/10.1056/NEJMoa1211851)
- Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol* 8: 101–112. doi:[10.1038/nrm2101](https://doi.org/10.1038/nrm2101)
- Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, Segel M, Nemesh J, et al (2019) Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. *Immunity* 50: 253–271.e6. doi:[10.1016/j.immuni.2018.11.004](https://doi.org/10.1016/j.immuni.2018.11.004)
- Hanseuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, et al (2019) Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. *JAMA Neurol* 76: 915–924. doi:[10.1001/jamaneurol.2019.1424](https://doi.org/10.1001/jamaneurol.2019.1424)
- Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskva V, Dowzell K, Williams A, et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* 41: 1088–1093. doi:[10.1038/ng.440](https://doi.org/10.1038/ng.440)
- He Y, Yao X, Taylor N, Bai Y, Lovenberg T, Bhattacharya A (2018) RNA sequencing analysis reveals quiescent microglia isolation methods from postnatal mouse brains and limitations of BV2 cells. *J Neuroinflammation* 15: 153. doi:[10.1186/s12974-018-1195-4](https://doi.org/10.1186/s12974-018-1195-4)
- He Y, Zheng MM, Ma Y, Han XJ, Ma XQ, Qu CQ, Du YF (2012) Soluble oligomers and fibrillar species of amyloid β -peptide differentially affect cognitive functions and hippocampal inflammatory response. *Biochem Biophys Res Commun* 429: 125–130. doi:[10.1016/j.bbrc.2012.10.129](https://doi.org/10.1016/j.bbrc.2012.10.129)
- Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement* 14: 535–562. doi:[10.1016/j.jalz.2018.02.018](https://doi.org/10.1016/j.jalz.2018.02.018)
- Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A, Muhs A, Lashuel HA (2011) Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. *J Biol Chem* 286: 8585–8596. doi:[10.1074/jbc.M110.172411](https://doi.org/10.1074/jbc.M110.172411)
- Jan A, Gokce O, Luthi-Carter R, Lashuel HA (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. *J Biol Chem* 283: 28176–28189. doi:[10.1074/jbc.M803159200](https://doi.org/10.1074/jbc.M803159200)
- Jarosz-Griffiths HH, Noble E, Rushworth JV, Hooper NM (2016) Amyloid- β receptors: The good, the bad, and the prion protein. *J Biol Chem* 291: 3174–3183. doi:[10.1074/jbc.R115.702704](https://doi.org/10.1074/jbc.R115.702704)
- Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, Ruano D, Vizuete M, Gutierrez A, Vitorica J (2008) Inflammatory response in the hippocampus of PS1m146l/app751sl mouse model of Alzheimer's disease: Age-dependent switch in the microglial phenotype from alternative to classic. *J Neurosci* 28: 11650–11661. doi:[10.1523/JNEUROSCI.3024-08.2008](https://doi.org/10.1523/JNEUROSCI.3024-08.2008)
- Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, et al (2014) Coding variants in TREM2 increase risk for Alzheimer's disease. *Hum Mol Genet* 23: 5838–5846. doi:[10.1093/hmg/ddu277](https://doi.org/10.1093/hmg/ddu277)

- Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, Lincoln S, Krishnan S, Kachadoorian M, Reitz C, et al (2015) TREM2 is associated with increased risk for Alzheimer's disease in African Americans. *Mol Neurodegener* 10: 19. doi:[10.1186/s13024-015-0016-9](https://doi.org/10.1186/s13024-015-0016-9)
- Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med* 368: 107–116. doi:[10.1056/NEJMoa1211103](https://doi.org/10.1056/NEJMoa1211103)
- Kassambara A (2020) ggpubr: 'ggplot2' based publication ready plots. <https://CRAN.R-project.org/package=ggpubr>.
- Kayed R, Lasagna-Reeves CA (2013) Molecular mechanisms of amyloid oligomers toxicity. *J Alzheimers Dis* 33: S67–S78. doi:[10.3233/JAD-2012-129001](https://doi.org/10.3233/JAD-2012-129001)
- Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al (2017) A unique microglia type Associated with restricting development of Alzheimer's disease. *Cell* 169: 1276–1290.e17. doi:[10.1016/j.cell.2017.05.018](https://doi.org/10.1016/j.cell.2017.05.018)
- Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, et al (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. *Immunity* 47: 566–581.e9. doi:[10.1016/j.immuni.2017.08.008](https://doi.org/10.1016/j.immuni.2017.08.008)
- Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, et al (2019) Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet* 51: 414–430. doi:[10.1038/s41588-019-0358-2](https://doi.org/10.1038/s41588-019-0358-2)
- Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* 41: 1094–1099. doi:[10.1038/ng.439](https://doi.org/10.1038/ng.439)
- Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* 45: 1452–1458. doi:[10.1038/ng.2802](https://doi.org/10.1038/ng.2802)
- Langfelder P, Horvath S (2008) WGCNA: An R package for weighted correlation network analysis. *BMC Bioinformatics* 9: 559. doi:[10.1186/1471-2105-9-559](https://doi.org/10.1186/1471-2105-9-559)
- Langfelder P, Horvath S (2012) Fast R functions for robust correlations and hierarchical clustering. *J Stat Softw* 46. doi:[10.18637/jss.v046.i11](https://doi.org/10.18637/jss.v046.i11)
- Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ (2013) Software for computing and annotating genomic ranges. *PLoS Comput Biol* 9: e1003118. doi:[10.1371/journal.pcbi.1003118](https://doi.org/10.1371/journal.pcbi.1003118)
- Li Q, Cheng Z, Zhou L, Darmanis S, Neff NF, Okamoto J, Gulati G, Bennett ML, Sun LO, Clarke LE, et al (2019) Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. *Neuron* 101: 207–223.e10. doi:[10.1016/j.neuron.2018.12.006](https://doi.org/10.1016/j.neuron.2018.12.006)
- Li S, Selkoe DJ (2020) A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A β oligomers from Alzheimer's brain. *J Neurochem* 154: 583–597. doi:[10.1111/jnc.15007](https://doi.org/10.1111/jnc.15007)
- Lin L, Desai R, Wang X, Lo EH, Xing C (2017) Characteristics of primary rat microglia isolated from mixed cultures using two different methods. *J Neuroinflammation* 14: 101. doi:[10.1186/s12974-017-0877-7](https://doi.org/10.1186/s12974-017-0877-7)
- Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. *Nat Rev Neurol* 9: 106–118. doi:[10.1038/nrneurol.2012.263](https://doi.org/10.1038/nrneurol.2012.263)
- Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15: 550. doi:[10.1186/s13059-014-0550-8](https://doi.org/10.1186/s13059-014-0550-8)
- Morgan M, Pages H, Obenchain V, Hayden N (2018) Rsamtools: Binary alignment (BAM), FASTA, variant call (BCF), and tabix file import. R package version 1.32.0. <http://bioconductor.org/packages/release/bioc/html/Rsamtools.html>.
- Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, Cimpean M, Khairallah A, Coronas-Samano G, Sankowski R, et al (2020) Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease. *Nat Commun* 11: 6129. doi:[10.1038/s41467-020-19737-2](https://doi.org/10.1038/s41467-020-19737-2)
- Perlmuter LS, Scott SA, Barrón E, Chui HC (1992) MHC class II-positive microglia in human brain: Association with Alzheimer lesions. *J Neurosci Res* 33: 549–558. doi:[10.1002/jnr.490330407](https://doi.org/10.1002/jnr.490330407)
- Rammes G, Hasenjaeger A, Sroka-Saidi K, Deussing JM, Parsons CG (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β -amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. *Neuropharmacology* 60: 982–990. doi:[10.1016/j.neuropharm.2011.01.051](https://doi.org/10.1016/j.neuropharm.2011.01.051)
- Rosario AM, Cruz PE, Ceballos-Diaz C, Strickland MR, Sieminski Z, Pardo M, Schob KL, Li A, Aslanidi GV, Srivastava A, et al (2016) Microglia-specific targeting by novel capsid-modified AAV6 vectors. *Mol Ther Methods Clin Dev* 3: 16026. doi:[10.1038/mtm.2016.26](https://doi.org/10.1038/mtm.2016.26)
- Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, Mancuso R, Chen WT, Woodbury ME, Srivastava A, et al (2019) The major risk factors for Alzheimer's disease: Age, sex, and genes modulate the microglia response to A β plaques. *Cell Rep* 27: 1293–1306.e6. doi:[10.1016/j.celrep.2019.03.099](https://doi.org/10.1016/j.celrep.2019.03.099)
- Shen L (2020) GeneOverlap: Test and visualize gene overlaps. R Package version 1.26.0.
- Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, et al (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nat Genet* 49: 1373–1384. doi:[10.1038/ng.3916](https://doi.org/10.1038/ng.3916)
- Stine WB, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. *J Biol Chem* 278: 11612–11622. doi:[10.1074/jbc.M210207200](https://doi.org/10.1074/jbc.M210207200)
- Strickland SL, Morel H, Prusinski C, Allen M, Patel TA, Carrasquillo MM, Conway OJ, Lincoln SJ, Reddy JS, Nguyen T, et al (2020) Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. *Acta Neuropathol Commun* 8: 172. doi:[10.1186/s40478-020-01050-0](https://doi.org/10.1186/s40478-020-01050-0)
- Tham CS, Lin FF, Rao TS, Yu N, Webb M (2003) Microglial activation state and lysophospholipid acid receptor expression. *Int J Dev Neurosci* 21: 431–443. doi:[10.1016/j.ijdevneu.2003.09.003](https://doi.org/10.1016/j.ijdevneu.2003.09.003)
- Tseng BP, Esler WP, Clish CB, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW, Lee JP, Maggio JE (1999) Deposition of monomeric, not oligomeric, A β mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. *Biochemistry* 38: 10424–10431. doi:[10.1021/bi990718v](https://doi.org/10.1021/bi990718v)
- van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleiheidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, et al (2019) A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. *Acta Neuropathol* 138: 237–250. doi:[10.1007/s00401-019-02026-8](https://doi.org/10.1007/s00401-019-02026-8)
- van Helmond Z, Miners JS, Kehoe PG, Love S (2010) Oligomeric A β in Alzheimer's disease: Relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. *Brain Pathol* 20: 468–480. doi:[10.1111/j.1750-3639.2009.00321.x](https://doi.org/10.1111/j.1750-3639.2009.00321.x)
- Vickers JC, Mitew S, Woodhouse A, Fernandez-Martos CM, Kirkcaldie MT, Canty AJ, McCormack GH, King AE (2016) Defining the earliest pathological changes of Alzheimer's disease. *Curr Alzheimer Res* 13: 281–287. doi:[10.2174/1567205013666151218150322](https://doi.org/10.2174/1567205013666151218150322)

- Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoëke C, Macaulay SL, Martins R, Maruff P, et al (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. *Lancet Neurol* 12: 357–367. doi:[10.1016/S1474-4422\(13\)70044-9](https://doi.org/10.1016/S1474-4422(13)70044-9)
- Walsh DM, Selkoe DJ (2007) A beta oligomers: A decade of discovery. *J Neurochem* 101: 1172–1184. doi:[10.1111/j.1471-4159.2006.04426.x](https://doi.org/10.1111/j.1471-4159.2006.04426.x)
- Wang ZX, Tan L, Liu J, Yu JT (2016) The essential role of soluble A β oligomers in Alzheimer's disease. *Mol Neurobiol* 53: 1905–1924. doi:[10.1007/s12035-015-9143-0](https://doi.org/10.1007/s12035-015-9143-0)
- Waters J (2010) The concentration of soluble extracellular amyloid- β protein in acute brain slices from CRND8 mice. *PLoS One* 5: e15709. doi:[10.1371/journal.pone.0015709](https://doi.org/10.1371/journal.pone.0015709)
- Webers A, Heneka MT, Gleeson PA (2020) The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease. *Immunol Cell Biol* 98: 28–41. doi:[10.1111/imcb.12301](https://doi.org/10.1111/imcb.12301)
- Wickham H (2016) *ggplot2: Elegant Graphics for Data Analysis*. New York: Springer-Verlag. <https://ggplot2.tidyverse.org>
- Young MD, Wakefield MJ, Smyth GK, Oshlack A (2010) Gene ontology analysis for RNA-seq: Accounting for selection bias. *Genome Biol* 11: R14. doi:[10.1186/gb-2010-11-2-r14](https://doi.org/10.1186/gb-2010-11-2-r14)
- Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci* 34: 11929–11947. doi:[10.1523/JNEUROSCI.1860-14.2014](https://doi.org/10.1523/JNEUROSCI.1860-14.2014)

License: This article is available under a Creative Commons License (Attribution 4.0 International, as described at <https://creativecommons.org/licenses/by/4.0/>).